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Background/Aims: The hepatic steatosis index (HSI) is a noninvasive method to assess the 
severity of hepatic steatosis. Antiviral therapy (AVT) can impact aspartate aminotransferase and 
alanine aminotransferase levels, which are the main components of the HSI. Thus, we investi-
gated the accuracy of the HSI in detecting hepatic steatosis in patients with chronic hepatitis B 
(CHB) receiving AVT, compared with those not receiving AVT and in those with nonalcoholic fatty 
liver disease (NAFLD).
Methods: Patients with CHB or NAFLD who underwent a magnetic resonance imaging proton 
density fat fraction (MRI-PDFF) evaluation between March 2010 and March 2019 were recruited. 
Hepatic steatosis was diagnosed when the PDFF exceeded 5%. Area under the receiver operat-
ing characteristic curve (AUROC) analysis was used to assess the diagnostic accuracy of the 
HSI in the detection of hepatic steatosis.
Results: The mean age of the study population (189 men and 116 women; 244 with CHB [184 
with and 60 without AVT] and 61 with NAFLD) was 55.6 years. The AUROC values for detect-
ing hepatic steatosis were similar between patients with CHB (0.727; p<0.001) and those with 
NAFLD (0.739; p=0.002). However, when patients with CHB were subdivided into those receiving 
and not receiving AVT, the AUROC value decreased slightly in patients with CHB receiving AVT 
compared to those without not receiving AVT (0.707; p=0.001 vs 0.779; p=0.001).
Conclusions: Despite a slight attenuation, the diagnostic accuracy of the HSI in patients with 
CHB receiving AVT in detecting hepatic steatosis was still acceptable. Further large-scale studies 
are required for validation. (Gut Liver 2021;15:117-127)
Key Words: Hepatic steatosis index; Fatty liver; Hepatitis B; Antiviral therapy; Nonalcoholic fatty 
liver disease
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is one of the 
most common causes of chronic liver disease worldwide.1,2 
With improvements in living standards and lifestyle chang-
es, NAFLD has become increasingly prevalent, occurring 
in 20% to 30% of the general population.3 Recent reports 
indicate that the prevalence of NAFLD in Asian counties 
is similar to the worldwide occurrence rate, and chronic 
hepatitis B (CHB) is a substantial public health concern in 
these countries.4
Accurate assessment of hepatic steatosis is important 
regardless of the presence or absence of underlying liver 
disease. The co-existence of hepatic steatosis and CHB 
may accelerate disease progression, influence the efficacy 
of antiviral treatment, and increase the risk of developing 
cirrhosis and hepatocellular carcinoma.5,6 Liver biopsy is 
the gold standard for assessing the severity of hepatic ste-
atosis, but the efficacy and applicability of this procedure 
is significantly hampered by its invasive nature and the 
tendency for sampling errors to occur.7,8 Although con-
ventional ultrasonography has been widely used as a first-
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line diagnostic tool for hepatic steatosis, there are several 
factors that diminish the effectiveness of this technique.9-11 
These include a low sensitivity in detecting hepatic steato-
sis at an early stage and substantial interoperator discrep-
ancies in the measurements acquired during the imaging.
Recently, controlled attenuation in transient elastogra-
phy and magnetic resonance imaging-proton density fat 
fraction (MRI-PDFF) measurements have emerged as ac-
curate, highly reproducible, and noninvasive surrogates in 
the evaluation of hepatic steatosis in various chronic liver 
diseases, including NAFLD.12-15 However, the high cost of 
the devices required for these evaluations has limited their 
widespread clinical use. Accordingly, several noninvasive 
diagnostic indices based on biochemical laboratory test 
results or demographic characteristics have been proposed 
to assess the severity of hepatic steatosis.16 Of these indi-
ces, the hepatic steatosis index (HSI) is an economical and 
noninvasive means for assessing the severity of hepatic ste-
atosis with reasonable accuracy.17 The constituent variables 
of the HSI include sex, alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), body mass index (BMI), 
and diabetic status. A recent Chinese study reported a 
greater accuracy of the HSI for detecting biopsy-proven 
hepatic steatosis when compared to ultrasound (area 
under the receiver operating characteristic curve [AU-
ROC]=0.755 for moderate-to-severe hepatic steatosis and 
0.786 for severe hepatic steatosis).18 Another study found 
a significant positive correlation between the HSI and the 
histopathological grade of hepatic steatosis in patients with 
chronic hepatitis C infection.19
However, it is not clear whether the acceptable accuracy 
of the HSI persists in the presence of a therapeutic inter-
vention, which can significantly affect the biochemical 
markers measured by noninvasive surrogates. Therefore, 
we investigated the accuracy of the HSI for evaluating 
hepatic steatosis in patients with CHB receiving antiviral 
therapy (AVT) when compared to those not receiving 
AVT, and to those with NAFLD.
MATERIALS AND METHODS
1. Patients
Between March 2010 and March 2019, patients with 
CHB or NAFLD who underwent MRI-PDFF evaluations 
at Severance Hospital, Yonsei University College of Medi-
cine, Seoul, Korea were considered for eligibility in this 
retrospective, cross-sectional study.
The exclusion criteria were as follows: (1) the presence 
of other etiologies of chronic liver disease other than CHB 
or NAFLD, (2) age ≤19 years, (3) insufficient clinical or 
laboratory information, (4) insufficient information for 
calculating HSI, (5) hepatocellular carcinoma or hepatic 
decompensation at enrollment or a history of either condi-
tion, (6) a history of organ transplantation, or (7) signifi-
cant alcohol consumption (defined as >21 drinks per week 
in men and >14 drinks per week in women).20
The study protocol was consistent with the ethical 
guidelines of the Declaration of Helsinki and was approved 
by the Institutional Review Board of Severance Hospital 
(IRB number: 4-2019-0639). Informed consent was waived 
in this study due to its retrospective design.
2. Estimation of hepatic steatosis severity
Ultrasonographically diagnosed NAFLD was defined 
according to ultrasonographic findings such as echogenic 
or bright liver on imaging consistent with fatty infiltra-
tion.21 The severity of hepatic steatosis was evaluated using 
the HSI, which was calculated as follows: HSI=8×(ALT/
AST ratio)+BMI (+2, if female; +2, if diabetes mellitus).17 
In addition, hepatic steatosis was also assessed using MRI-
PDFF and a diagnosis of hepatic steatosis was made when 
the PDFF exceeded 5%.22 
3. Diagnosis of liver cirrhosis and dyslipidemia
Liver cirrhosis was diagnosed based on ultrasono-
graphic findings. These included findings such as altered 
parenchymal echogenicity with coarsened echotexture and 
surface nodularity, caudate hypertrophy, splenomegaly, 
and slow portal vein mean flow velocity.23,24 A diagnosis of 
dyslipidemia was made when low-density lipoprotein cho-
lesterol was ≥160 mg/dL, total cholesterol was ≥240 mg/
dL, or total triglyceride was ≥200 mg/dL.25
4. Statistical analysis
The patients’ demographic and laboratory data were 
summarized as means±standard deviation for continuous 
variables, and as medians with percentages for categorical 
variables. Correlation analysis between fat fraction and 
other variables were conducted using the Pearson method. 
Mean and frequency data were compared using an inde-
pendent samples t-test or chi-square test. Logistic binary 
regression analysis was conducted to identify independent 
predictors of fatty liver. AUROC analysis was implemented 
to assess the diagnostic accuracy of the HSI for hepatic ste-
atosis. All statistical analyses were performed using SPSS 
version 23.0 software (IBM Corp., Armonk, NY, USA). A 
p-value <0.05 was considered statistically significant.




Among the 1,437 patients who received MRI-PDFF, 
805 patients with other etiologies of chronic liver diseases, 
other than CHB or NAFLD, were excluded. Further, 327 
patients were removed from our study population accord-
ing to our established exclusion criteria. As a result, a final 
total of 305 patients were selected for the statistical analysis 
(Fig. 1).
The baseline characteristics of the study population 
(189 males and 116 females; 244 with CHB [184 with AVT 
and 60 without AVT] and 61 NAFLD) are shown in Table 
1. The median age, BMI, HSI, and fat fraction as deter-
mined by MRI-PDFF of the study participants were 55.6 
years, 25.5 kg/m2, 34.7, and 3.3%, respectively. A total of 83 
patients (27.2%) had fatty liver based on the MRI-PDFF. 
A total of 36 (14.8%) patients with CHB had ultrasono-
graphic fatty liver. The respective baseline characteristics of 
patients with NAFLD and CHB are summarized in Table 1.
2. Comparison between patients with NAFLD and 
CHB
The baseline characteristics of patients with NAFLD 
and those with CHB were analyzed and compared (Table 
1). Patients with NAFLD were significantly younger (mean: 
50.3 years vs 56.9 years) and had a significantly lower pro-
portion of male gender (47.5% vs 65.6%), a higher BMI 
(mean: 27.5 kg/m2 vs 25.0 kg/m2), a higher proportion of 
diabetes (49.2% vs 23.4%), and a lower proportion of liver 
cirrhosis (52.5% vs 86.1%) than those with CHB (all com-
parisons p<0.05). In addition, patients with NAFLD had a 
lower total bilirubin level (mean: 0.8 mg/dL vs 1.0 mg/dL), 
a higher AST level (mean: 40.7 U/L vs 29.1 U/L), a higher 
ALT level (mean: 44.6 U/L vs 28.0 U/L), a higher platelet 
count (mean: 212 ×109/L vs 146 ×109/L), a higher HSI 
(mean: 38.1 vs 33.8), a higher fat fraction by MRI-PDFF 
(9.9% vs 1.6%), and a higher proportion of fatty liver by 
MRI-PDFF (62.3% vs 18.4%) than those of patients with 
CHB (all comparisons p<0.05) (Fig. 2).
3. Comparison between patients with CHB receiving 
AVT and those not receiving AVT
The baseline characteristics of patients with CHB re-
ceiving AVT and those not receiving AVT were compared 
(Table 1). Patients with CHB receiving AVT were signifi-
cantly younger (mean: 56.2 years vs 59.2 years) and had a 
significantly lower BMI (mean: 24.7 kg/m2 vs 25.9 kg/m2), 
a higher proportion of liver cirrhosis (89.7% vs 75.0%) and 
HBeAg positivity (26.4% vs 5.6%), and a lower proportion 
of fatty liver by MRI-PDFF (14.7% vs 30.0%) than that 
those not receiving AVT (all comparisons p<0.05) (Fig. 2).
4.  Correlations between fat fraction and other 
variables
In the entire study population, the fat fraction as deter-
mined by MRI-PDFF showed a significant positive corre-
lation with platelet count, HSI, ALT, BMI, serum albumin, 
total cholesterol, diabetes, AST, and total protein (all cor-
relations p<0.05). There was a significant negative correla-
tion between fat fraction as determined by MRI-PDFF and 
the presence of liver cirrhosis, age, and total bilirubin (all 
correlations p<0.05) (Supplementary Table 1).
In patients with NAFLD, fat fraction as determined by 
MRI-PDFF showed a significant positive correlation with 
serum albumin, ALT, total cholesterol, and HSI. In con-
trast, fat fraction as determined by MRI-PDFF presented 
with a significant negative correlation with age, hyper-
tension, and presence of liver cirrhosis (all correlations, 
both positive and negative, p<0.05) (Table 2). In patients 
1,437 Patients who received MRI-PDFF
Other etiologies of chronic liver diseases except CHB of NAFLD
632 Patients with CHB of NAFLD
305 Patients were analyzed
Age 19 years
Insufficient clinical of laboratory information
Insufficient information for calculating HSI
HCC of hepatic decompensation at enrollment of a history of either
History of organ transplantation
Significant alcohol consumption
Fig. 1. A graphical representation 
of the patient selection process. Of 
1,437 patients who received MRI-
PDFF, 305 were selected for the 
statistical analysis according to our 
exclusion criteria. 
MRI-PDFF, magnetic resonance 
imaging-proton density fat fraction; 
CHB, chronic hepatitis B; NAFLD, 
nonalcoholic fatty liver disease; HSI, 
hepatic steatosis index; HCC, hepa-
tocellular carcinoma.




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Chang JW, et al: Hepatic Steatosis Index in Patients with Chronic Hepatitis B
https://doi.org/10.5009/gnl19301  121
with CHB, fat fraction presented with a significant posi-
tive correlation with BMI, presence of dyslipidemia, total 
cholesterol and HSI, and a significant negative correlation 
with the presence of liver cirrhosis (all p<0.05) (Table 2). 
The correlation between fat fraction and other variables in 
patients with CHB receiving AVT and those not receiving 
AVT are listed in Table 2.
5. Predictors of the presence of fatty liver
In entire study population, a higher platelet count (odds 
ratio [OR], 1.012; 95% confidence interval [CI], 1.006 to 
1.019) and higher HSI (OR, 1.155; 95% CI, 1.076 to 1.240) 
predicted the presence of fatty liver (all comparisons 
p<0.05) (Supplementary Table 2).
In patients with NAFLD, age, hypertension, and liver 
cirrhosis were negatively associated with the presence of 
fatty liver, whereas serum albumin level, platelet count, and 
HSI were positively associated with the presence of fatty 
liver in univariate analysis (all p<0.05). No predictor of 
fatty liver was identified in multivariate analysis (Table 3).
In all patients with CHB, a higher platelet count (OR, 
1.009; 95% CI, 1.002 to 1.017) and a higher HSI (OR, 1.163; 
95% CI, 1.069 to 1.266) independently predicted the pres-
ence of fatty liver (all p<0.05) (Table 4). When patients 
with CHB were stratified into two groups with and without 
AVT, a higher HSI was the only predictor of fatty liver in 
CHB patients without AVT (OR, 1.241; 95% CI, 1.044 to 
1.014; p=0.014), whereas a higher platelet count (OR, 1.011; 
95% CI, 1.003 to 1.019) and a higher HSI (OR, 1.142; 95% 
CI, 1.027 to 1.269) independently predicted the presence of 





























Fig. 2. The prevalence of fatty liver as assessed using MRI-PDFF 
(magnetic resonance imaging-proton density fat fraction). 
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6. Diagnostic accuracy of HSI and other variables in 
the diagnosis of fatty liver
The diagnostic accuracy of the HSI was assessed in each 
subgroup (Table 5, Fig. 3). In NAFLD group, platelet count 
had the highest AUROC value in the diagnosis of fatty 
liver (AUROC, 0.886; 95% CI, 0.793 to 0.978), followed 
by the HSI (AUROC, 0.739; 95% CI, 0.613 to 0.865) (both 
p<0.05). In CHB group, AUROC value of platelet count 
was also highest (AUROC, 0.733; 95% CI, 0.658 to 0.808), 
and that of HSI was second (AUROC, 0.727; 95% CI, 0.649 
to 0.805), but the difference of both values was less than 
that in NAFLD group.
When patients with CHB were divided into two groups 
with or without AVT, the AUROC of the HSI in diagnos-
ing fatty liver was increased in patients not receiving AVT 
(AUROC, 0.779; 95% CI, 0.651 to 0.907), whereas it was 
decreased in patients receiving AVT (AUROC, 0.707; 95% 
CI, 0.608 to 0.805), when compared to the overall AUROC 
of all patients with CHB (all comparisons p<0.05).
7.  Cutoff value for the HSI in the diagnosis of fatty 
liver
The calculated cutoff values of the HSI which maxi-
mized the sum of sensitivity and specificity and the pro-
portion of patients with fatty liver are summarized in 
Table 6. The cutoff values ranged from 33.1 to 33.9 in the 
subgroups and the HSI accurately predicted fatty liver in 
60.3% to 73.8% of patients. We then implemented the gen-
erally accepted cutoff value of 36 to diagnose fatty liver,17 
and the changes in diagnostic indices are summarized in 
Table 6.
DISCUSSION
Liver biopsy has been regarded as the ‘gold standard’ for 
assessing the severity of liver disease.26 However, due to its 
invasive nature and the resultant complications, it has not 
exhibited a widespread application in clinical practice.27 
Radiological assessment using ultrasonography, computed 
tomography, and magnetic resonance imaging have been 
shown to accurately assess the degree of liver fibrosis or 
steatosis.28-31 However, this noninvasive procedure also has 
limitations, including the required specialized equipment 
and high cost of assessment. As such, varying simple and 
noninvasive tests have been proposed and validated in the 
identification of patients who are at a high risk of incurring 
NAFLD.17 Of these tests, we focused our investigation on 
the accuracy of the HSI with simple constituent variables, 
based on the fat quantity assessed using MRI-PDFF, to 
diagnose the presence of NAFLD in patients with NAFLD 
and CHB with or without AVT.17
It is currently accepted that the presence of hepatic 
steatosis in patients with CHB is significantly associated 
with a non-physiological response to AVT and acceler-
ated liver fibrosis progression.5,32,33 Further, there remains a 
substantial need for noninvasive predictors of fatty liver in 
patients with CHB, and recently several noninvasive surro-
gates, such as the HSI, have been implemented.34 However, 
these surrogate tests rely on biochemical laboratory results, 
results such as AST or ALT, which are significantly influ-
enced by AVT in patients with CHB. Thus, the diagnostic 
accuracy of the HSI should be confirmed in patients with 
CHB undergoing AVT. To this end, the aim of our study 
was to investigate the diagnostic accuracy of the HSI utiliz-
ing NAFLD patients as a control group, and comparing the 
accuracy of the test between NAFLD patients and those 
with CHB. In addition, we investigated whether the accu-
racy of the HSI is altered by AVT in patients with CHB.
In our study, we found that the AUROC values for de-
tecting hepatic steatosis were similar between patients with 
CHB and those with NAFLD (0.727 vs 0.739). This indi-
cates that there is good applicability for the HSI in patients 
with CHB. However, the accuracy of the HSI in NAFLD 
patients in this study seems relatively low when compared 
to the original study which proposed the HSI for the diag-
Table 3. Predictors of the Presence of Fatty Liver in Patients with NAFLD 
Variable
Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Age, yr 0.920 (0.882–0.960) <0.001 0.972 (0.907–1.041) 0.415
Hypertension 0.230 (0.076–0.694) 0.009 0.562 (0.064–4.943) 0.603
Liver cirrhosis 0.109 (0.031–0.390) 0.001 0.877 (0.093–8.270) 0.909
Dyslipidemia 0.429 (0.114–1.612) 0.210 - -
Total bilirubin, mg/dL 0.537 (0.164–1.753) 0.303 - -
Serum albumin, g/dL 33.588 (4.027–280.164) 0.001 9.477 (0.293–306.421) 0.205
Platelet count, ×109/L 1.027 (1.013–1.040) <0.001 1.012 (0.997–1.028) 0.116
Hepatic steatosis index 1.211 (1.067–1.375) 0.003 1.161 (0.958–1.407) 0.128
NAFLD, nonalcoholic fatty liver disease; OR, odds ratio; CI, confidence interval.
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nosis of fatty liver (AUROC, 0.812).17 However, when pa-
tients with CHB were subdivided into those with or with-
out AVT, the AUROC value decreased slightly in patients 
with CHB receiving AVT compared to those without AVT 
(0.707 vs 0.779). However, the AUROC values remained 
within an acceptable range for both groups.
Our study has several clinical implications. First, the 
prevalence of fatty liver assessed using MRI-PDFF was 
only 62.3% in the ultrasonography defined NAFLD group. 
The accuracy of MRI-PDFF is noted to be highly signifi-
cant in recent studies,22,35,36 and as such this discrepancy in 
the diagnosis of fatty liver is likely due to false positivity of 
ultrasonography in cases with increased hepatic parenchy-
mal echogenicity. The coarse parenchymal echogenicity in 
chronic liver disease is often misdiagnosed as the diffuse 
increased parenchymal echogenicity in fatty liver. How-
ever, as there remains a significant overlap in diagnosing 
fatty liver between two modalities, no predictor was identi-
fied to detect MRI-PDFF-based fatty liver in the ultrasono-
graphically defined NAFLD group.
Second, we found a significant relationship between 
the presence of hepatic steatosis and platelet count in our 
study. The platelet count was significantly higher in pa-
tients with NAFLD and those with CHB (mean: 212×109/
L vs 146×109/L). Further, there was a significant correla-
tion between platelet count and fat fraction as determined 
by MRI-PDFF. After adjustment, the diagnostic value of 
platelet count remained significant across the entire study 
population (OR, 1.012) and in those with CHB (OR, 1.009). 






































































































































































































































































































































































































































































Table 5. Accuracy of the HSI and Other Variables to Diagnose Fatty 
Liver
Predictor AUROC 95% CI p-value
NAFLD
   HSI 0.739 0.613–0.865 0.002
   Age, yr 0.154 0.055–0.254 <0.001
   Platelet count, ×109/L 0.886 0.793–0.978 <0.001
All HBV
   HSI 0.727 0.649–0.805 <0.001
   Age, yr 0.464 0.371–0.557 0.451
   Platelet count, ×109/L 0.733 0.658–0.808 <0.001
HBV without AVT
   HSI 0.779 0.651–0.907 0.001
   Age, yr 0.394 0.250–0.537 0.194
   Platelet count, ×109/L 0.679 0.538–0.821 0.029
HBV with AVT
   HSI 0.707 0.608–0.805 0.001
   Age, yr 0.465 0.341–0.589 0.563
   Platelet count, ×109/L 0.744 0.652–0.835 <0.001
HSI, hepatic steatosis index; AUROC, area under the receiver operat-
ing characteristic curve; CI, confidence interval; NAFLD, nonalcoholic 
fatty liver disease; HBV, hepatitis B virus; AVT, antiviral therapy.
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the highest AUROC values in our study. Our results are 
supported by findings from previous studies which have 
demonstrated that platelet count has a positive correlation 
with hepatic steatosis.37,38 In addition, this phenomenon 
might be associated with the burn-out theory indicating 
that hepatic steatosis is reduced in advanced fibrosis or 
cirrhosis stage in the natural history of NAFLD.39 Platelets 
are active participants in the process of liver inflammation, 
promoting leukocyte recruitment through hepatic sinu-
soids, and activating effector cells.40
Third, we quantified fat content using MRI-PDFF 
which is the gold standard technique for this measurement. 
Although other histological features, such as necroinflam-
mation or fibrosis, cannot be detected by MRI-PDFF, 
MRI-PDFF has been shown to be a precise, accurate, and 
reproducible noninvasive imaging surrogate for the quan-
tification of liver fat content.41-43 Performing a liver biopsy 
to establish liver fat content is not clinically feasible, and as 
such our strategy in using the MRI-PDFF for the diagnosis 
of fatty liver, in the determination of the diagnostic accu-
racy of the HSI, is particularly relevant.
Finally, in patients with NAFLD, the accuracy of the cal-
culated prediction rate using our own HSI cutoff (33.9) in 
the diagnosis of fatty liver was higher than that presented 
previously calculated using a predefined HSI cutoff (36) 
(73.8% vs 62.3%).17 In contrast, in patients with CHB, the 
correctly predicted rate calculated using our own HSI cut-
off (33.4) to diagnose fatty liver was relatively lower than 
that calculated using the predefined HSI cutoff (36) (62.7% 
vs 71.7%). Similar findings were observed in the subgroup 
analysis of those with CHB undergoing or not undergo-
ing AVT. Although the precise reason for this discrepancy 
according to the etiology of specific chronic liver disease 
might be unclear, one of the reasons may be the differ-
ent proportion of patients with various severity of liver 
diseases. However, our data suggests that the predefined 
Fig. 3. ROC curves of the HSI for the diagnosis of fatty liver in patients with NAFLD and CHB receiving or not receiving AVT. (A) AUROC=0.739 in 
NAFLD patients, (B) AUROC=0.727 in all patients with CHB, (C) AUROC=0.779 in patients with CHB not receiving AVT, and (D) AUROC=0.707 in pa-
tients with CHB receiving AVT. 
ROC, receiver operating characteristic; HSI, hepatic steatosis index; NAFLD, nonalcoholic fatty liver disease; CHB, chronic hepatitis B; AVT, antivi-
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HSI cutoff value of 36 can be used in the diagnosis of fatty 
liver in patients with CHB, while this value may require 
some modification to enhance its accuracy in patients 
with NAFLD. Therefore, we suggest that further validation 
studies are warranted to establish and confirm the optimal 
HSI cutoff values for the various etiologies of chronic liver 
disease.
We are also aware of some limitations of our study 
which remain unresolved. First, our study has a retrospec-
tive design. Thus, the decision to prescribe MRI-PDFF 
may be different according to the etiology of chronic liver 
diseases. Indeed, MRI-PDFF could have been performed 
in patients with NAFLD, whereas it was only done in pa-
tients with CHB as a surveillance imaging technique in 
the detection of hepatocellular carcinoma.44 Accordingly, 
the overall diagnostic accuracy of HSI in our study might 
have been significantly influenced due to the high propor-
tion of patients with MRI PDFF-based fatty liver (about 
62%). In addition, the high prevalence of cirrhotic patients 
might have been caused by selection bias. Indeed, in our 
study, MRI-PDFF was mostly performed for patients with 
advanced fibrosis or cirrhosis, as well as those with poor 
ultrasonographic echo window, or suspicious co-existing 
hepatic nodules. All of these issues should be resolved in 
future prospective studies that includes the general popu-
lation and all patients with full spectrum of the diseases 
(simple steatosis and NASH in NAFLD patients and inac-
tive and active phases in CHB patients).
Second, our study contains a relatively small sample 
size. This is particularly true when the study population 
was divided according to the etiology of chronic liver dis-
eases and AVT status. Large prospective studies will be 
required to resolve this issue and validate our results. 
Third, due to the heterogeneity in the type and duration 
of hepatotonics, we could not investigate their potential 
influence on the accuracy of the HSI. In addition, the lack 
of histological information could be a significant limitation 
of this study. 
In conclusion, the diagnostic accuracy of the HSI in pa-
tients with NAFLD was acceptable. Further, despite a slight 
decrease in accuracy, the diagnostic accuracy of the HSI 
in patients with CHB receiving AVT was still acceptable in 
detecting hepatic steatosis. Future larger scale studies will 
be required for the validation of our results.
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Table 6. Cutoff Value of the HSI Used to Diagnose Fatty Liver





Patients with fatty liver, No. (%) 38 (62.3) 45 (18.4) 18 (30.0) 27 (14.7)
Calculated cutoff value 33.9 33.4 33.1 33.4
   Sensitivity, % 86.8 84.4 83.3 85.2
   Specificity, % 52.2 57.8 61.9 56.1
   Positive predictive value, % 75.0 31.2 48.4 25.0
   Negative predictive value, % 70.6 94.3 89.7 95.7
   Positive likelihood ratio 1.82 2.00 2.19 1.94
   Negative likelihood ratio 0.25 0.27 0.27 0.26
   Correctly predicted, % 73.8 62.7 68.3 60.3
Predefined cutoff value of HSI >36
   Patients with HSI >36, No. (%) 28 (45.9) 78 (32.0) 10 (16.7) 58 (31.5)
   Sensitivity, % 65.8 60.0 61.1 59.3
   Specificity, % 54.3 74.4 78.6 73.3
   Positive predictive value, % 71.4 34.6 55.0 27.6
   Negative predictive value, % 50.0 89.2 82.5 91.3
   Positive likelihood ratio 1.51 2.34 2.85 2.22
   Negative likelihood ratio 0.61 0.54 0.49 0.56
   Correctly predicted, % 62.3 71.7 73.3 71.2
HSI, hepatic steatosis index; NAFLD, nonalcoholic fatty liver disease; HBV, hepatitis B virus; AVT, antiviral therapy.
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